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Abstract: Psoriasis is a skin disease that is accompanied by oxidative stress resulting in modification of
cell components, including proteins. Therefore, we investigated the relationship between the intensity
of oxidative stress and the expression and activity of the proteasomal system as well as autophagy,
responsible for the degradation of oxidatively modified proteins in the blood cells of patients with
psoriasis. Our results showed that the caspase-like, trypsin-like, and chymotrypsin-like activity of
the 20S proteasome in lymphocytes, erythrocytes, and granulocytes was lower, while the expression
of constitutive proteasome and immunoproteasome subunits in lymphocytes was increased cells of
psoriatic patients compared to healthy subjects. Conversely, the expression of constitutive subunits in
erythrocytes, and both constitutive and immunoproteasomal subunits in granulocytes were reduced.
However, a significant increase in the autophagy flux (assessed using LC3BII/LC3BI ratio) independent
of the AKT pathway was observed. The levels of 4-HNE, 4-HNE-protein adducts, and proteins
carbonyl groups were significantly higher in the blood cells of psoriatic patients. The decreased
activity of the 20S proteasome together with the increased autophagy and the significantly increased
level of proteins carbonyl groups and 4-HNE-protein adducts indicate a proteostatic imbalance in the
blood cells of patients with psoriasis.
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1. Introduction
Psoriasis is a chronic inflammatory autoimmune disease of the skin and joints. Its pathogenesis is
thought to include interactions between genetic factors (for example, the HLACw6 and HLACw7 tissue
compatibility complex alleles) and environmental factors such as bacterial or viral infections, injuries,
and stress [1]. Psoriasis is mediated by T cells, dendritic cells, neutrophils, and other leukocytes.
In psoriasis, inflammatory cytokines, such as interleukins IL-23 and IL-6, are produced by dendritic
cells and macrophages. These cytokines facilitate the differentiation of Th17 cells, which secrete IL-17
and other mediators that stimulate the hyperproliferation of epidermal cells and contribute to abnormal
keratinocyte differentiation [2]. In addition, proinflammatory signaling pathways such as MAPK/AP-1,
NF-κB, and JAK-STAT are activated in cells involved in the development of psoriatic lesions [3–5].
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One group of factors that modulate cell signaling pathways are reactive oxygen species (ROS),
which are constantly generated as a result of normal cellular metabolism, but are produced at increased
quantities as a result of exogenous factors and metabolic disorders [6]. Under physiological conditions,
the effect of ROS is balanced by the activity of endogenous antioxidants. However, overproduction
or prolonged action of ROS leads to oxidative stress and, as a result, oxidative modifications of
biologically active cell components, including DNA, lipids, and proteins [7]. Many studies have
revealed elevated levels of markers of oxidative damage in the serum/plasma and blood cells of patients
with psoriasis [8–14]. Additionally, there is a positive correlation between oxidative stress markers
and psoriasis area and disease severity index [15]. Recent reports have confirmed that psoriasis
is accompanied by enhanced lipid peroxidation, demonstrated by the increased generation of α,β
unsaturated reactive aldehydes (e.g., 4-HNE) that form adducts with proteins. These products may
play an important role in the pathophysiology of psoriasis [11,12,16].
Under oxidative conditions, when the amount of oxidatively modified proteins increases,
the activity of proteolytic systems (especially the 20S and 26S proteasome system and autophagy) is
essential to ensure proteostasis. When the performance of these systems is disturbed, misfolded and
aggregated proteins can accumulate to toxic levels and cause cell dysfunction, potentially leading
to the development of many diseases [17]. However, as well as increasing the level of modified
proteins, oxidative stress may also promote the increased activity of proteasomes. As evidence of this,
it has been demonstrated under conditions of permanent oxidative stress, the 26S proteasome and the
ubiquitinating system are deactivated [7]. The 20S proteasome degrades oxidatively modified proteins
without ubiquitination [18]. Multiple studies from a number of laboratories have independently
confirmed that the main pathway for the degradation of oxidatively damaged proteins in cells is via
the 20S proteasome [19–21].
The 20S proteasome consists of α and β subunits. Three of the β subunits (β1, β2, β5) contain
catalytic sites that perform various proteolytic activities [18]. These are classified as caspase-like
(β1), trypsin-like (β2), and chymotrypsin-like (β5) as defined by the presence of their cleavage sites
after acidic, basic, or hydrophobic amino acids, respectively [22]. However, after exposure of cells to
proinflammatory factors (interferon-γ (IFN-γ) or tumor necrosis factor (TNFα)), three catalytic 20S
subunits are replaced with homologous subunits, β1i (LMP2), β2i (MECL1), and β5i (LMP7) to form an
immunoproteasome with enhanced chymotrypsin-like activity (β1i and β5i) and trypsin-like activity
(β2i) [23]. The immunoproteasome is involved in the pathogenesis of inflammatory diseases [24] and is
also responsible for degrading oxidatively damaged proteins. The biogenesis of the immunoproteasome
is strongly induced during adaptation to oxidative stress [25], and it is constitutively expressed in cells
of lymphoid origin [26].
In addition to the degradation of oxidized proteins, the proteasome is involved in the regulation of
many other signaling pathways, including cell differentiation, proliferation, and apoptosis, as well as
transcription activation and angiogenesis [27]. One of the best-studied roles of an immunoproteasome
is in antigen presentation, and immunoproteasome dysfunction can lead to numerous immune and
inflammatory diseases [28]. The development of psoriasis has been linked with allelic variation in
β1i, and β5i 20S proteasome subunits [29]. The expression and activity of the 20S proteasome are
also increased in psoriatic skin cells [30]. Consistent with these findings, the selective proteasome
inhibitor PS-519 prevents IκB degradation and inhibits downstream NF-κB signaling, reducing T
cell activation in vitro and in vivo. Thus, it is effective in the treatment of psoriasis in the murine
SCID-hu model [31]. In contrast, bortezomib, a different proteasome inhibitor, exacerbates symptoms
in an imiquimod-induced psoriasis (IMQ) model [32]. Inhibition of proteasomes may induce a
proinflammatory response, which manifests in increased cyclooxygenase-2 activity and prostaglandin
E2 production [33]. The proteasome negatively regulates the transcription of inflammatory mediators
regulated by the atypical, redox-dependent stimulus of the NF-κB pathway [34]. In addition, mutations
in the proteasome subunits cause autoinflammatory disorders such as Nakajo-Nishimura syndrome
and chronic atypical neutrophilic dermatosis [35].
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Therefore, the study aimed to link the severity of oxidative stress (assessed by the level of lipid
peroxidation and oxidative protein modifications) with the expression of the proteasomal system and
autophagy in the blood cells of psoriasis patients.
2. Results
2.1. S Proteasome Subunit Expression and Activity in Blood Cells From Psoriatic Patients
The constitutive 20S proteasome contains three β subunits which perform caspase-like (β1),
trypsin-like (β2), and chymotrypsin-like (β5) activities, whereas the immunoproteasome has three
inducible subunits which exhibit chymotrypsin-like (β1i and β5i) and trypsin-like (β2i) activities.
The development of psoriasis favored a significant increase in the expression of the constitutive
catalytic subunits β1, β2, and β5 in lymphocytes. The most substantial increase (more than 3-fold) was
in the expression of the β1 subunit (Figure 1). A significant increase in β1i subunit expression and a
modest increase in the level of β2i and β5i subunits of the immunoproteasome were also observed.
In contrast, we observed over 50% reduction in caspase-like activity, for which the β1 subunit is
responsible. Moreover, both the chymotrypsin-like activity attributed to β5, β1i, and β5i subunits,
as well as the trypsin-like activity associated with β2 and β2i subunits, were reduced (by approximately
60% and 30%, respectively) compared to the cells of healthy people.
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Figure 1. (A) Expression of the constitutive proteasome (β1, β2, β5) and immunoproteasome (β1i, 
β2i, β5i) subunits in lymphocytes from patients with psoriasis (n = 6), in comparison to healthy 
subjects (control), (n = 6). (B) Caspase-like (Cas-L), trypsin-like (T-L), and chymotrypsin-like (ChT-L) 
activities of the proteasomes in lymphocytes from patients with psoriasis (n = 16) and healthy 
subjects (control), (n = 12). Values in (A) and (B) are expressed as a percentage of control. ∗—statistical significance at p < 0.05 vs. control. 
Figure 1. (A) Expression of the constitutive proteasome (β1, β2, β5) and immunoproteasome (β1i, β2i,
β5i) subunits in lymphocytes from patients with psoriasis (n = 6), in comparison to healthy subjects
(control), (n = 6). (B) Caspase-like (Cas-L), trypsin-like (T-L), and chymotrypsin-like (ChT-L) activities
of the proteasomes in lymphocytes from patients with psoriasis (n = 16) and healthy subjects (control),
(n = 12). Values in (A) and (B) are expressed as a percentage of control. ∗—statistical significance at
p < 0.05 vs. control.
In the granulocytes of patients with psoriasis, the expression of constitutive subunits β1 and β2
and inducible subunits β1i and β5i was significantly reduced (50%) compared to healthy subjects
(Figure 2). These changes were accompanied by a significant decrease (50%) in all three types of
proteasomal activities (i.e., chymotrypsin-like, trypsin-like, caspase-like).
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Figure 2. (A) Expression of the constitutive proteasome (β1, β2, β5) and immunoproteasome (β1i, β2i,
β5i) subunits in granulocytes from patients with psoriasis (n = 6), in comparison to healthy subjects
(control), (n = 6). (B) Caspase-like (Cas-L), trypsin-like (T-L), and chymotrypsin-like (ChT-L) activities
of the proteasomes in granulocytes from patients with psoriasis (n = 16) and healthy subjects (control),
(n = 12). Values in (A) and (B) are expressed as a percentage of control. ∗—statistical significance at
p < 0.05 vs. control.
In contrast to lymphocytes and granulocytes, erythrocytes do not contain immunoproteasomes [36].
The expression of the 20S proteasome constitutive catalytic subunit β5 was significantly reduced
(by about 30%), while β2 andβ1 showed only a slight reduction in erythrocytes of psoriasis patients
(Figure 3) compared to healthy controls. All three 20S proteasome activities were significantly reduced
(chymotrypsin-like by around 50%, trypsin-like by around 60%, and caspase-like by 70%).
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The serine-threonine kinase AKT plays a central role in the regulation of cell survival in a 
variety of diseases. AKT phosphorylates key molecules involved in the regulation of autophagy, and 
the AKT/mTOR pathway is one of the major activators of macroautophagy (Figure 5). Our data 
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Figure 3. (A) Expression of the constitutive proteasome (β1, β2, β5) and immunoproteasome (β1i, β2i,
β5i) subunits in erythrocytes from patients with psoriasis (n = 6), in comparison to healthy subjects
(control), (n = 6). (B) Caspase-like (Cas-L), trypsin-like (T-L), and chymotrypsin-like (ChT-L) activities
of the proteasomes in erythrocytes from patients with psoriasis (n = 16) and healthy subjects (control),
(n = 12). Values in (A) and (B) are expressed as a percentage of control. ∗—statistical significance at
p < 0.05 vs. control.
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2.2. Autophagy-Associated Protein Expression in Blood Cells From Psoriatic Patients
The LC3B protein is an autophagy marker that has two forms (LC3B-I and LC3B-II). Following the
activation of autophagy, LC3B is cleaved after the C-terminal glycine by ATG4 family proteins to
form LC3-I and then conjugated with phosphatidylethanolamine to form LC3-II (Figure 4). Due to
variability in the basal levels of LC3B in different cells, the ratio of LC3BII/LC3BI is used to assess the
severity of autophagy. Lymphocytes and erythrocytes from patients with psoriasis show a significantly
increased LC3BII/LC3BI ratio (about 3 and 4 times, respectively) compared to healthy individuals,
while granulocytes have a similar LC3BII/LC3BI ratio in the control and psoriasis group.
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Figure 4. The ratio of LC3BII/LC3BI expression in lymphocytes (L), erythrocytes (E), and granulocytes
(G) from psoriatic patients (n = 6), in comparison to healthy subjects (control), (n = 6). Values are
expressed as a percentage of control. ∗—statistical significance at p < 0.05 vs. control.
The erin -threonine kinase AKT plays a central role in the regulation of cell survival in a variety
of diseases. AKT phosphorylates key molecules involved in the regulation of autophagy, and the
AKT/mTOR pat way is one of the major activators of macroautophagy (Figure 5). O r dat show
a eduction in phosphorylation of AKT in erythrocytes and gra ulocytes (by about 70% nd 30%,
respectively) but not in l mphocytes of psoriatic patient .
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conditions favor the oxidative modifications of the cellular components, including proteins, lipids, 
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Figure 5. Phosphorylated AKT (pAKT)/AKT expression ratio in lymphocytes (L), erythrocytes (E),
and granulocytes (G) from psoriatic patients (n = 6), in comparison to healthy subjects (control), (n = 6).
Values are expressed as a percentage of control. ∗—statistical significance at p < 0.05 vs. control.
2.3. Protein Modifications in Blood Cells From Psoriatic Patients
Oxidative stress ca potentiate lipid peroxidation. One of the end products of lipid peroxidation
is 4-HNE, which can make adducts with proteins. Lymphocytes, erythrocytes, and granulocytes from
psoriatic patients have display 4-HNE concentrations that are two times higher than the blood cells
from healthy subjects (Figure 6).
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Figure 6. The level of 4-HNE (A), 4-HNE-protein adducts (B), and carbonylated proteins (C) in
erythrocytes (E, n = 68), lymphocytes (L, n = 20), and granulocytes (G, n = 20) of psoriatic patients
compared to healthy subjects (control) (E, n = 34, L, n = 10, and G, n = 10); ∗—statistical significance at
p < 0.05 vs. control.
3. Discussion
Psoriasis is an inflammatory immune disease with a pathogenesis that is incompletely understood.
However, it is clear that the development of this disease is accompanied by oxidative stress resulting
from inc eased ROS production and disruption of antioxidant protection both local in skin cells and
syst mic in blood c lls, as we have s own in previ us studies [11,12]. Such conditions favor the i ti
modifications of the cellul r components, including proteins, lipids, and DNA, and many studies
have shown elevated levels of oxidative stress markers in serum/plasma and blood cells (erythrocytes,
lymphocytes, and granulocytes) in patients with psoriasis [8–10,37]. In addition, a positive correlation
between oxidative stress mark rs and p oriatic skin rea and disease severity ind x has lso bee
observed [15].
Under oxidative con iti s, ROS interact directly with proteins, which causes both the oxidation
of amino ci sid chains and the breaking of p ptide bonds to form carbonyl groups [38]. The results
of this study demonstrate enhanced protein carbonylation in the blood cells of patients with psoriasis.
Protein carbonylation is also a result of t reaction of roteins with reactive aldehydes, which are
products of lipid peroxidation [16]. Phospholipids, especially their polyunsaturated fatty acids, are
extremely susceptible to ROS, and as a result of oxidative fragmentation of hydrocarbon chains of
these acids, reactive aldehydes are formed, including 4-HNE [39]. Elevated levels of 4-HNE were
observed in the blood cells (erythrocytes, granulocytes, and lymphocytes) of patients with psoriasis,
which confirms previous results showing the same effect in granulocytes and lymphocytes as well as
plasma of patients [11,12].
4-HNE has two electrophilic centers and, therefore, can react with nucleophilic fragments
of protein amino acid residues, mainly histidine, cysteine, and lysine, forming 4-HNE-protein
adducts [12,40], whose elevated levels are observed in all examined blood cells of patients with
psoriasis. The consequence of the formation of these adducts is a change in the structure of protein
molecules, including the formation of intra- and intermolecular bonds. These structural changes can
lead to protein cross-linking, which modifies the physicochemical and biological properties of proteins,
as well as decreasing their susceptibility to degradation [40,41]. Protein carbonylation is an irreversible
process, which means that damaged molecules are not repaired, and if they are not degraded, they can
strongly disrupt cellular metabolism [42]. It has been shown that as a result of oxidative modification
of protein molecules, their surface hydrophobicity increases, which is a key signal for the proteolytic
system to recognize the protein and initiate its degradation [43].
Modified proteins are degraded mainly by the proteasomal systems (20S and 26S) [44]. However,
during oxidative stress, the activity of the 26S proteasome decreases, while the activity of the
20S proteasome remains mostly unchanged [45]. Unsurprisingly, in many inflammatory diseases,
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dysregulation of proteasomal activity is observed [35,46]. Increased proteasome activity and expression
but stable mRNA levels has been demonstrated in psoriatic skin cells, which has led to the suggestion
that the expression of proteasomes and immunoproteasomes is post-transcriptionally regulated [30].
However, our study found a reduction in the caspase-, trypsin-, and chymotrypsin-like activities of the
20S proteasomes in blood cells of psoriatic patients, corresponding to increased levels of carbonylated
proteins and 4-HNE-protein adducts. It is possible that under intense oxidative stress, even the 20S
proteasome may not be sufficient to maintain efficient protein degradation. On the other hand, the 20S
proteasome may be subject to oxidative modification [44], causing the level of carbonyl groups to
negatively correlate with proteasome activity. This effect has been observed in HEK 293 cells [47]. It has
also been shown that modifications of proteasome structure by 4-HNE, and as a result of carbonylation,
S-glutathionylation, and glycoxidation, cause changes in the proteasome subunits, which affects 20S
proteasomal activity [48].
The results of this study show that increased oxidative modifications of cellular proteins are
accompanied by changes in the expression and activity of the catalytic subunits of the proteasome.
Increased expression of both constitutive and immunoproteasome catalytic subunits in lymphocytes
verifies that oxidative stress impacts proteasomes at the level of expression. The increase in proteasome
expression under stress conditions is accompanied by oxidative modification of the associated proteins,
leading to structural changes, consequently, reduced proteasomal activity. In addition, patients
with psoriasis have previously been shown to have elevated levels of anti-proteasome antibodies in
the blood [34], which may further reduce the activity of proteasomes, as demonstrated in in vitro
studies [49].
The accumulation of proteins modified in the development of psoriasis may lead to the modification
of signaling pathways. Such signaling pathways could include initiating inflammatory processes,
which could lead to cell death [7]. Moreover, protein adducts have antigenic properties, which means
that their proinflammatory effects may also be the result of the autoimmune response demonstrated in
rheumatoid arthritis [50]. It is known that proinflammatory signaling pathways such as MAPK/AP-1,
NF-κB, and JAK-STAT are involved in the development of psoriatic lesions [3–5]. Our previous studies
have shown elevated levels of NF-κB and proinflammatory cytokines in plasma and the blood cells
(granulocytes and lymphocytes) of patients with psoriasis [11,12]. However, adequate proteasomal
activity is required to activate the canonical NF-κB pathway. NF-κB remains in the cytoplasm due
to its interaction with the NF-κB inhibitor (IκB). When it is phosphorylated, IκB is degraded by the
proteasome, and free NF-κB is transported to the cell nucleus, where it controls the transcription of
proinflammatory genes [51]. However, the observed decrease in proteasomal activity may favor the
inhibition of canonical activation of NF-κB (IκB phosphorylation-dependent) and may instead activate
the unusual NF-κB pathway [52]. In our previous work, [11,13], we observed increased expression
of Keap1, which is a cytosolic inhibitor of another transcription factor—Nrf2—in granulocytes and
lymphocytes of patients with psoriasis, which may support the degradation of IκB [53]. Nrf2 causes the
transcriptional activation of several 20S proteasomal subunits as well as the PA28αβ (11S)—proteasomal
regulator [25] because the promoter regions of many 20S α and β subunits and PA28αβ subunits have
electrophile/antioxidant response elements domains consisting of the RTGACnnGG core motif or the
extended TMAnnRTGAYnnnGCAww motif [25]. Enhanced expression of Nrf-2 in lymphocytes of
patients with psoriasis [13], induces the expression of constitutive catalytic subunits [54]. This may at
least partly explain the increased protein expression of constitutive β1, β2, and β5 catalytic subunits in
lymphocytes of patients with psoriasis observed in this study. It is also known that oxidative stress
increases the expression of immunoproteasomes [26,55]. These findings may suggest that excessive
release of inflammatory cytokines may cause alteration in the conversion of the proteasome to the
immunoproteasome, which plays a role in the formation of peptides for presentation by MHC class I
proteins [56]. On the other hand, immunoproteasomes have also been shown to be required to reduce
inflammatory responses. However, our results also show a reduction of immunoproteasomal subunits
in granulocytes.
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In the degradation of damaged/modified proteins, the proteasomal system is supported by the
process of autophagy, which degrades, among others, protein aggregates that have not undergone
proteasomal proteolysis and may accumulate in cells [57,58]. Our findings indicate a significant
increase in autophagy units in the blood cells of patients with psoriasis. In contrast to the proteasomal
system, reactive oxygen species have been recognized as inducers of autophagy [59]. Therefore,
increased oxidative stress in the blood cells of patients with psoriasis leads to increased expression
of autophagic units, which in turn may also increase the degradation of 20S proteasome subunits,
especially those that have undergone oxidative modifications. The severity of autophagy may be
indicated by increased levels of phosphatidylethanolamines since it was previously found that the
level of degradation products of these phospholipids (lysophosphatidylethanolamines) is reduced in
psoriasis granulocytes [12]. In contrast, by coupling with LC3, phosphatidylethanolamines participate
in the formation of the autophagosomes necessary to start the protein degradation process [60].
Finally, elevated levels of ROS observed during the development of psoriasis may suppress
AKT phosphorylation, which, by inhibiting the mammalian target of rapamycin (mTOR) pathway,
causes autophagy activation. This effect was observed in our study, especially in granulocytes and
erythrocytes of patients with psoriasis. As a result, these actions weaken the inflammatory response
and stimulate the catabolic program of protein and cell growth [61–63]. Given the significant increase
in autophagy and the reduction in the number of erythrocytes and lymphocytes observed in patients
with psoriasis [64,65], cell death may be the final result of autophagy in these cases. Additionally,
it has been suggested that autophagy, like the proteasomal system, is closely related to the complex
network of NF-κB and Nrf2 transcription factors [66]. Autophagy could be required for the full
activation of NF-κB [67]. Therefore, several elements of the NF-κB system, including all IKK, NIK,
and p62SQSTM1 subunits, are simultaneously autophagic substrates. Autophagic degradation of IκB
appears to be needed as a prolonged response to NF-κB transcriptional activity [68]. Autophagy is
also regulated by the Nrf2 transcription factor, which induces the expression of p62 (an autophagic
sectosome 1 adapter) that interacts with the autophagic LC3 effector protein and is degraded by the
autophagic lysosome [69]. Studies on cancer cells suggest that cells accumulate p62 as a result of
inflammation [70]. We detected increased levels of both transcription factor Nrf2 and p62 in the blood
cells of patients with psoriasis [11,13,71].
The results of this study show a decrease in the activity and efficiency of the proteasomal
system in blood cells, which resulted in the accumulation of modified proteins e.g., in the form of
4-HNE-protein adducts and carbonylated proteins, which in turn can lead to modification the biological
activity of proteasomes [72]. Moreover, it is known that in the case of psoriasis, an overproduction
of chemoattractants by keratinocytes is observed, which results in increased migration of cells from
the bloodstream to the skin [2]. For this reason, infiltration with immune cells is observed in the
skin, what is an important element of psoriatic lesions and, consequently, the intensification of the
keratinocyte-leukocyte interaction. In psoriasis, oxidative stress and elevated levels of cytokines in both
the skin and blood are observed, suggesting that similar phenotypic changes occur in both peripheral
blood leukocytes and skin infiltrating leukocytes. However oxidative stress results in changes in
the conformation and activity of proteins involved in the regulation of transcription, modification
and transmission of signaling molecules, both intracellular as well as cytokines, which modifies
the interaction of immune cells with keratinocytes [2]. It was found that this applies especially to
proteins participating in the antioxidant response, what additionally increases the oxidative stress
in keratinocytes [11,12,16]. These changes are particularly important when modifying the Nrf2
transcription factor pathway, the increased activity of which has been described as a key factor in
the proliferation of keratinocytes in psoriasis [73]. On the other hand, intensification of autophagy,
especially in immune cells, most likely favors NF-κB activation [67], which results in an increase in
the production of pro-inflammatory cytokines, which then have a paracrine or endocrine effect on
keratinocytes, additionally strengthening the proinflammatory background of psoriasis development.
Therefore, the observed changes suggest strengthening of proliferative and inflammatory signal by
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direct connection of processes taking place in blood cells, especially immune and epidermal cells [2].
It may be suggested that this is important metabolic information indicative of the appearance/existence
of specific pathophysiological changes in keratinocytes and, consequently, may significantly support
the early diagnosis of psoriasis.
In summary, the reduction of 20S proteasome activity in the blood cells of patients with psoriasis
may be the result of the reduced expression of proteasome subunits. Additionally, structural modification
of these proteins as a result of their interaction with 4-HNE or ROS could also affect proteasome activity.
Concurrently, oxidative stress promotes impaired protein polyubiquitination and reduced degradation
of proteins by the 26S proteasome [7]. Thus, although the development of psoriasis is accompanied by
increased autophagy, the observed overexpression of total levels of carbonylated proteins and 4-HNE
protein adducts indicates a lack of proteostatic balance in the blood cells of patients with psoriasis.
We suggest that the use of antioxidant compounds in the treatment of psoriasis may support the
maintenance of metabolic homeostasis in the blood cells of patients.
4. Materials and Methods
4.1. Patients Characterization
Blood samples were obtained from 32 female and 36 male psoriasis patients (total: 68 individuals,
mean age: 38). The individuals had psoriasis for at least six months, with at least 10% of the total
body surface area affected. The control group consisted of 15 healthy female and 19 healthy male
individuals (total: 34 individuals, mean age: 38). The main exclusion criteria in all groups were the use
of topical or oral medication four weeks before the start of the study, and the presence of any illnesses,
smoking, or alcohol abuse. When analyzing the patient’s medical history, particular attention was
paid to currently used drugs (antiplatelet and anticoagulant drugs) and comorbidities (circulatory,
respiratory, liver, or kidney disease, as well as cancer and diabetes). The study was approved by
the Local Bioethics Committee at the Medical University of Bialystok (Poland), No. R-I-002/289/2017
(approved on 28 September 2017). Written informed consent was obtained from all the patients.
4.2. Blood Samples
Blood samples were taken into tubes containing ethylenediaminetetraacetic acid (EDTA).
Two-stage centrifugation was then carried out. In the first stage, the sample was centrifuged at
3000× g (4 ◦C) to obtain the plasma and the buffy coat. Erythrocytes, lymphocytes, and granulocytes
were isolated from the buffy coat by gradient centrifugation using Gradisol G/L (1:5 ratio). Samples were
layered on Gradisol and subjected to 25 min centrifugation at 300× g at room temperature. The individual
cell fraction was collected, washed, and resuspended in PBS containing proteasome inhibitor mix.
An antioxidant—butylhydroxytoluene (BHT)—was added to erythrocyte, lymphocyte, and granulocyte
samples before storing them to prevent oxidation. The total protein content in the cells lysate was
measured using a Bradford assay [74].
4.3. Proteasomal Activity
Blood cells were sonicated in lysis buffer containing 50 mM Tris-HCl (pH = 7.5), 1 mM EDTA,
1 mM ethylene-bis(oxyethylenenitrilo)tetraacetic acid EGTA, 0.5% Triton X, and centrifuged at 12,000× g
for 15 min at 4 ◦C. The supernatants were diluted to 2 mg protein/mL and assayed for proteasome
activity in the assay buffer containing 100 mM Tris/HCl pH = 7.5, 1 mM EDTA, 1 mM EGTA, using
the chymotrypsin-like activity substrate, Suc-LLVY-7-amino-4-methylcoumarin (Suc-LLVY-AMC;
Sigma-Aldrich, St. Louis, MO, USA), the trypsin-like activity substrate, Bz-VGR-AMC (Enzo Life
Sciences, Inc., Farmingdale, NY, USA), or the caspase-like activity substrate, Z-LLE-AMC (Enzo Life
Sciences, Inc., Farmingdale, NY, USA). All substrates were at a concentration of 100 µM in a final
volume of 50 µL [75]. All components were added to a black 96 well plate and incubated at 37 ◦C for
30 min. The released fluorogenic 7-amino-4-methylcoumarin (AMC) concentration was measured
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spectrofluorometrically [355 nm excitation and 460 nm emission] using a fluorometric plate reader
(EnSpire 2300 Multilabel Reader, PerkinElmer, Waltham, MA, USA). The amount of released AMC was
evaluated from the AMC reference curve, which allowed expression of proteasome activity in pmol
AMC/min/mg protein to be assessed. All tests were carried out in triplicate.
4.4. Protein Expression
Cell lysates were mixed with sample loading buffer (Laemmle buffer containing 5%
2-mercaptoethanol), heated at 95 ◦C for 10 min, and separated by 10% Tris-glycine SDS-PAGE.
The same procedure was used to prepare the negative control (containing pure PBS buffer) and the
positive control (commercially purchased complete cell lysate—Santa Cruz Biotechnology, Santa Cruz,
CA, USA). β-actin was used as an internal loading control. Separated proteins were electrophoretically
transferred onto nitrocellulose membranes. The blotted membranes were blocked with 5% skim milk
in TBS-T buffer (5% Tween-20) for 1 h. Primary antibodies against β-actin (Sigma-Aldrich, St. Louis,
MO, USA) and 20S β1, β1i, β2, β2i, β5, β5i subunits, LC3B, AKT, phosphorylated AKT (pAKT) (Enzo
Life Sciences, Inc., Farmingdale, NY, USA) were used at a concentration of 1:1000. After incubation
with primary antibodies, the membranes were then washed four times with TBS-T and incubated
with goat or mouse or rabbit polyclonal alkaline phosphatase secondary antibodies (Sigma-Aldrich;
St. Louis, MO, USA). Protein bands were visualized using the BCIP/NBT liquid substrate system
(Sigma-Aldrich, St. Louis, MO, USA) and quantitated using the Versa Doc System and Quantity One
software (Bio-Rad Laboratories Inc., Hercules, CA, USA). The results are expressed as a percentage of
the expression determined in control cells.
4.5. Determination of 4-HNE Level
The product of phospholipid oxidative fragmentation—4-HNE-was measured by gas
chromatography-mass spectrometry (GC-MS/MS GC-7000 quadrupole MS/MS, Agilent Technologies,
Santa Clara, CA, USA). The selected ion monitoring (SIM) mode was used, as the O-PFB-oxime-TMS
derivative, using minor modifications of the method of [76]. The following ions were used as follows:
m/z 333.0 and 181.0 for 4-HNE-PFB-TMS, m/z 204.0.
4.6. Measurement of 4-HNE-Protein Adducts Level
The level of 4-HNE-protein adducts was measured using the ELISA method. Anti-4-HNE-His
murine monoclonal antibody (genuine anti-4-HNE-His murine monoclonal antibody, clone 4-HNE
1g4) and goat anti-mouse antibody (Dako, Carpinteria, CA, USA) were used as primary and secondary
antibodies, respectively. The concentrations of 4-HNE–protein adducts were normalized for 1 mg
of protein.
4.7. Determination of Protein Carbonyl Groups Level
Protein oxidative modifications in plasma were estimated as the level of protein carbonyl groups
by spectrophotometry (370 nm) using 2,4-dinitrophenylhydrazine [77] and were expressed as nmoles
of carbonyl groups per mg of protein.
4.8. Statistical Analysis
An unpaired Student’s t-test was used to compare the mean values between conditions.
Differences were considered significant when p < 0.05.
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10. Sikar Aktürk, A.; Özdoğan, H.K.; Bayramgürler, D.; Çekmen, M.B.; Bilen, N.; Kıran, R. Nitric oxide and
malondialdehyde levels in plasma and tissue of psoriasis patients. J. Eur Acad Dermatol Venereol 2012, 26,
833–837. [CrossRef]
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